AR and prostate carcinoma: Androgen receptor (AR) plays a central role in prostate cancer (PCa) development, and androgen deprivation therapy (ADT) to reduce levels of circulating androgens (testosterone and dihydrotestosterone, DHT) is the standard treatment for metastatic PCa.